ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)

ClinicalTrials.gov ID: NCT01844518

Public ClinicalTrials.gov record NCT01844518. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 8:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Multi-center, Open-Label Study to Evaluate Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)

Study identification

NCT ID
NCT01844518
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
219 participants

Conditions and interventions

Interventions

  • Abatacept Biological

Biological

Eligibility (public fields only)

Age range
2 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 29, 2013
Primary completion
Mar 11, 2015
Completion
Jan 31, 2023
Last update posted
Jul 11, 2023

2013 – 2023

United States locations

U.S. sites
12
U.S. states
12
U.S. cities
12
Facility City State ZIP Site status
Local Institution - 0007 Birmingham Alabama 35233-1711
Local Institution - 0003 Little Rock Arkansas 72202
Local Institution - 0011 Hartford Connecticut 06106
Local Institution - 0009 Chicago Illinois 60637
Riley Hospital For Children Indianapolis Indiana 46202
University Of Kansas Medical Center Kansas City Kansas 66160
Local Institution - 0001 Kansas City Missouri 64108
Local Institution - 0002 The Bronx New York 10467
Local Institution - 0008 Cincinnati Ohio 45229
Local Institution - 0005 Portland Oregon 97227
Local Institution - 0004 Salt Lake City Utah 84132
Seattle Children'S Hospital Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01844518, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 11, 2023 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01844518 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →